Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ON open-label extension of BI 1015550 for IPF and PPF
MOH_2024-04-21_013377Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Any adverse event during the extension study. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on MOH_2024-04-21_013377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-21_013377.